A significant recent legal ruling by U.S. District Judge Angel Kelley has permanently prevented the National Institutes of Health (NIH) from capping indirect research cost funding at 15%, a move that would have caused substantial financial repercussions for research institutions. If the proposed
Recent developments in a high-profile legal battle have temporarily suspended the Department of Health and Human Services’ (HHS) plan to cut over $11 billion in public health funding for states. This critical decision underscores the ongoing importance of federal support for a wide array of
The Trump administration's substantial adjustment to Medicare Advantage (MA) plan payment rates has ignited discussions across the healthcare and financial sectors. A notable increase of 5.1%, incentivized by higher spending patterns in Medicare, has led to considerable financial and regulatory
The growing concern among Americans regarding government efforts to protect personal data has become a significant issue, with many feeling that their sensitive information is not adequately safeguarded. A recent report by Malwarebytes has highlighted these concerns, revealing that a substantial
A Senate committee hearing with HHS Secretary Robert F. Kennedy Jr. has been postponed due to the required seven-day notice not being met. The hearing, initially scheduled for April 10, was set to discuss the restructuring of the health department that Kennedy ordered. This restructuring has led to
James Maitland is an expert in pharmaceutical litigation and regulatory affairs, with a specific focus on how Pharmacy Benefit Managers (PBMs) influence the U.S. prescription drug market. Today, he shares his insights into the recent decision by Andrew Ferguson to rejoin the FTC's lawsuit against
